AstraZeneca has impressed oncology patient groups, rising to second place on PatientView’s corporate reputation ranking on the back of strength in breast and lung cancer. | AstraZeneca has impressed ...
Contract manufacturing powerhouse Lonza is growing in more ways than one. | Contract manufacturing powerhouse Lonza is growing in more ways than one. The Swiss company revealed this week that it is ...
After a site visit by FDA inspectors yielded a Form 483 for Genzyme Ireland in early 2026, the Sanofi subsidiary is facing further reprimand from the U.S. regulator. | After a site visit by FDA ...
Welcome to Fierce Pharma's regulatory tracker for the second half of 2026. | In this tracker, Fierce Pharma is recording the regulatory progress of in-market products, including expansions into key ...
Consumer health giant Haleon has tapped Microsoft to incorporate AI across its operations, joining a growing wave of healthcare and life sciences heavyweights turning to Big Tech ...
To help BridgeBio ramp up for the launch of three new medicines, plus approved ATTR-CM med Attruby, Sixth Street and HealthCare Royalty have agreed to invest up to $1 billion in the California biotech ...
Orca Bio has jumped into the commercial market with FDA approval for Tregzi, a first-of-its-kind engineered cell therapy for blood cancer patients requiring transplants. Tuesday, the FDA approved the ...
AstraZeneca will pay $34 million to resolve a lawsuit that alleged the company used illegal kickbacks to induce providers to ...
As Amgen’s rare disease medicine Tavneos comes under intensifying pressure from the FDA, the company faces a new hurdle with ...
Biopharma giants Eli Lilly and Regeneron and rapidly growing contract manufacturers Fujifilm and Cellares are among the seven ...
Despite a recent failure as a second-line monotherapy in diffuse B-cell lymphoma (DLBLC), a positive phase 3 combination ...
The FDA has issued a complete response letter to Unicycive over the “same third-party manufacturing deficiencies that were ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results